A Phase 2 interventional study of UT-15C SR and Tyvaso Inhalation Solution in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-27.
Sponsored by United Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 30th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 2, and was the 19th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2011.
This study's enrollment of 18 is below the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 30th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2011, is one of 9 in phase 2, and was the 24th registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this multi-center, open-label, safety and tolerability study was to assess the addition of oral treprostinil (UT-15C sustained release [SR] tablets) to subjects currently receiving Tyvaso (treprostinil) inhalation solution. During the 24-week evaluation period, the study evaluated the changes in the following assessments: hemodynamics, 6-minute walk test (6MWT), Borg dyspnea score, N-Terminal pro-brain natriuretic peptide (NT-proBNP), World Health Organization (WHO) Functional Class, and safety assessments.
Eligible subjects had a diagnosis of pulmonary arterial hypertension (PAH), currently were receiving Tyvaso, and may have been receiving other approved PAH specific oral therapies (endothelin receptor antagonists [ERAs] and/or phosphodiesterase type 5 inhibitor [PDE5-I], if at a stable dose for ≥30 days). At Baseline, subjects received the first dose of 0.125 mg UT-15C SR.
This was a multi-center, open-label, safety and tolerability study in WHO Group 1 PAH subjects adding UT-15C SR to Tyvaso and PAH approved background therapy. This study had a 24-week evaluation period followed by a long term safety period. Six study visits occurred in the first 24 weeks of study; Screening, Baseline, Week 4, Week 8, Week 12, and Week 24 visits. Right heart catheterization occurred between 2-4 hours following the last Tyvaso dose at Baseline (prior to the administration of UT-15C SR) and Week 24.
Significant inclusion criteria included:
Significant exclusion criteria included:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initiated at 0.125 mg twice daily (BID), titrated as clinically indicated.
Drug: UT-15C SR · Drug: Tyvaso Inhalation Solution
Initiated at 0.125 mg BID, titrated as clinically indicated.
Also known as: treprostinil diethanolamine, sustained release
Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline
Also known as: Treprostinil
Change in Hemodynamic Parameters From Baseline to Week 24.
Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included the following: mean pulmonary arterial pressure (PAPm), mean systemic arterial pressure (SAPm), mean right atrial pressure (RAPm), and mean pulmonary capillary wedge pressure (PCWPm).
Time frame: Baseline and Week 24
Change in Hemodynamic Parameter (Heart Rate) From Baseline to Week 24.
Heart rate was assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit.
Time frame: Baseline and Week 24
Change in Hemodynamic Parameters (Arterial and Venous Oxygen Saturation) From Baseline to Week 24.
Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included arterial oxygen saturation (SaO2) and mixed venous oxygen saturation (SvO2).
Time frame: Baseline and Week 24
Change in Hemodynamic Parameter (Cardiac Output) From Baseline to Week 24.
Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit.
Time frame: Baseline and Week 24
Change in Hemodynamic Parameter (Cardiac Index) From Baseline to Week 24.
Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included cardiac index (CI).
Time frame: Baseline and Week 24
Change in Hemodynamic Parameter (Pulmonary Vascular Resistance Index) From Baseline to Week 24.
Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included the following: pulmonary vascular resistance index (PVRI).
Time frame: Baseline and Week 24
Change in Exercise Capacity as Measured by the 6-minute Walk Test (6MWT) Over the 24-week Treatment Period.
The 6MWT was conducted at Baseline, 2 to 4 hours after the last Tyvaso dose, and prior to first dose of UT-15C SR. The 6MWT was also performed at Weeks 4, 12, and 24, or at the time of premature termination of study drug if prior to the Week 24 visit.
Time frame: Baseline and Weeks 4, 12, and 24
Time to Clinical Worsening Over the Treatment Period.
Clinical worsening was assessed continuously from Baseline through each subject's last study visit. Clinical worsening was defined as the occurrence of any one or more of the following: death (all causes), hospitalization as a result of worsening pulmonary arterial hypertension (PAH), and initiation of a parenteral prostacyclin.
Time frame: Clinical worsening was assessed continuously from Baseline through each subject's last study visit
Shift From Baseline in World Health Organization (WHO) Functional Class Over the 24-week Treatment Period.
The WHO functional classification for pulmonary hypertension was assessed at Baseline prior to starting UT-15C SR, Weeks 4, 8, 12, and 24, or at the time of premature termination if prior to Week 24. The WHO functional classification ranges from I (patient's disease does not affect daily activities) to IV (patient's disease causes severe impairment).
Time frame: Baseline and Weeks 4, 8, 12, and 24
N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Over the 24-week Treatment Period.
NT-proBNP was assessed at Baseline prior to starting UT-15C SR, Weeks 12 and 24, or at the time of premature termination if prior to Week 24. Blood for NT-proBNP assessment was collected before the 6MWT was conducted.
Time frame: Baseline and Weeks 12 and 24
The recruitment period for this study was October 2011 to November 2013.
| Milestone | UT-15C SR BID |
|---|---|
| Started | 18 |
| Completed | 15 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Clinical deterioration | 1 |
Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included the following: mean pulmonary arterial pressure (PAPm), mean systemic arterial pressure (SAPm), mean right atrial pressure (RAPm), and mean pulmonary capillary wedge pressure (PCWPm).
| mmHg | UT-15C SR BID |
|---|---|
| Systolic systemic arterial pressure (mmHg) | -2.0 (-22 to 21) |
| Diastolic systemic arterial pressure (mmHg) | 0 (-20 to 18) |
| Mean systemic arterial pressure (mmHg) | -1.0 (-29 to 18) |
| Systolic pulmonary arterial pressure (mmHg) | 3.0 (-51 to 12) |
| Diastolic pulmonary arterial pressure (mmHg) | 0 (-16 to 10) |
| Mean pulmonary arterial pressure (mmHg) | 0 (-26 to 10) |
| Mean right atrial pressure (mmHg) | 0 (-9 to 6) |
| Mean pulmonary capillary wedge pressure (mmHg) | -1.0 (-15 to 8) |
The 6MWT was conducted at Baseline, 2 to 4 hours after the last Tyvaso dose, and prior to first dose of UT-15C SR. The 6MWT was also performed at Weeks 4, 12, and 24, or at the time of premature termination of study drug if prior to the Week 24 visit.
| Meters | UT-15C SR BID |
|---|---|
| Week 4 | 20.5 (-111 to 119) |
| Week 12 | 12.4 (-70 to 101) |
| Week 24 | 14.9 (-178 to 101) |
Clinical worsening was assessed continuously from Baseline through each subject's last study visit. Clinical worsening was defined as the occurrence of any one or more of the following: death (all causes), hospitalization as a result of worsening pulmonary arterial hypertension (PAH), and initiation of a parenteral prostacyclin.
| Days | UT-15C SR BID |
|---|---|
| Time to Clinical Worsening Over the Treatment Period. | 234 ± 200.3 |
The WHO functional classification for pulmonary hypertension was assessed at Baseline prior to starting UT-15C SR, Weeks 4, 8, 12, and 24, or at the time of premature termination if prior to Week 24. The WHO functional classification ranges from I (patient's disease does not affect daily activities) to IV (patient's disease causes severe impairment).
| participants | Class II to Class II | Class II to Class III | Class III to Class II | Class III to Class III |
|---|---|---|---|---|
| Week 4 | 8 | 1 | 0 | 9 |
| Week 8 | 6 | 3 | 2 | 7 |
| Week 12 | 9 | 0 | 1 | 8 |
| Week 24 | 7 | 1 | 2 | 5 |
NT-proBNP was assessed at Baseline prior to starting UT-15C SR, Weeks 12 and 24, or at the time of premature termination if prior to Week 24. Blood for NT-proBNP assessment was collected before the 6MWT was conducted.
| pg/mL | UT-15C SR BID |
|---|---|
| Week 12 | -99 ± 295 |
| Week 24 | 144 ± 464 |
Heart rate was assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit.
| beats/min | UT-15C SR BID |
|---|---|
| Change in Hemodynamic Parameter (Heart Rate) From Baseline to Week 24. | 4.00 (-29.0 to 25.0) |
Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included arterial oxygen saturation (SaO2) and mixed venous oxygen saturation (SvO2).
| percentage bound to hemoglobin | UT-15C SR BID |
|---|---|
| Arterial oxygen saturation (%) | 1.0 (-5 to 5) |
| Mixed venous oxygen saturation (%) | 0 (-9 to 4) |
Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit.
| L/min | UT-15C SR BID |
|---|---|
| Change in Hemodynamic Parameter (Cardiac Output) From Baseline to Week 24. | 0 (-1 to 4) |
Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included cardiac index (CI).
| L/min/m^2 | UT-15C SR BID |
|---|---|
| Change in Hemodynamic Parameter (Cardiac Index) From Baseline to Week 24. | 0 (0 to 1) |
Hemodynamics (via right heart catheterization \[RHC\]) were assessed at Baseline and Week 24 or at the time of premature termination of study drug if prior to the Week 24 visit. Cardiopulmonary hemodynamic measurements included the following: pulmonary vascular resistance index (PVRI).
| dyn*s/cm^5*m^2 | UT-15C SR BID |
|---|---|
| Change in Hemodynamic Parameter (Pulmonary Vascular Resistance Index) From Baseline to Week 24. | 0.2 (-10 to 7) |
Collected over Adverse events were recorded throughout the 24-week study, including the screening phase, as well as during the long-term follow-up period.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| UT-15C SR BID | — | 2/18 (11.1%) | 18/18 (100%) |
| Event | UT-15C SR BID |
|---|---|
| AscitesGastrointestinal disorders | 1/18 |
| DiarrheaGastrointestinal disorders | 1/18 |
| Fluid overloadMetabolism and nutrition disorders | 1/18 |
| HyponatremiaMetabolism and nutrition disorders | 1/18 |
| Renal failure acuteRenal and urinary disorders | 1/18 |
| MalnutritionMetabolism and nutrition disorders | 1/18 |
| Event | UT-15C SR BID |
|---|---|
| HeadacheNervous system disorders | 14/18 |
| NauseaGastrointestinal disorders | 12/18 |
| DiarrheaGastrointestinal disorders | 11/18 |
| FlushingVascular disorders | 8/18 |
| FatigueGeneral disorders | 6/18 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 5/18 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/18 |
| Edema peripheralGeneral disorders | 4/18 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 4/18 |
| Abdominal painGastrointestinal disorders | 3/18 |
| Age, Categorical(Participants) | UT-15C SR BID |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 14 |
| >=65 years | 4 |
| Age, Continuous(years) | UT-15C SR BID |
|---|---|
| Mean | 51.3 (20 to 70) |
| Sex: Female, Male(Participants) | UT-15C SR BID |
|---|---|
| Female | 13 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | UT-15C SR BID |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | UT-15C SR BID |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 18 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | UT-15C SR BID |
|---|---|
| United States | 18 |
The record gives a start of Oct 2011, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →